BACKGROUND: Although decennial adult boosters of tetanus and diphtheria toxoids are recommended in Canada and the United States, a second dose of pertussis vaccine is not currently recommended for adults. METHODS: This open-label, postmarketing, multicenter study evaluated the tolerability and immunogenicity of a second dose of an adult formulation of tetanus, diphtheria, and pertussis vaccine (Tdap) in adolescents and adults 5 years after a first dose. RESULTS: A total of 545 participants from previous Tdap vaccine studies, ranging in age from 15 to 69 years, participated in this study. Of these participants, 94.2% had at least one solicited adverse event after the booster dose such as injection-site erythema (28.6%), swelling (25.6%), or pain (87.6%) or a systemic adverse event such as myalgia (61.0%), headache (53.2%), malaise (38.2%), or fever (6.5%). These adverse events were slightly more frequent than after the initial dose. Postvaccination, 100% of participants had a tetanus antibody level ≥0.10IU/mL and 95% had a diphtheria antibody level ≥0.10IU/mL. For pertussis, 82.1% (pertussis toxoid), 96.7% (filamentous hemagglutinin), 95.6% (pertactin), and 99.8% (fimbriae) had a postvaccination antibody threshold of ≥50EU/mL. CONCLUSION: A second dose of Tdap vaccine 5 years after the initial dose was well tolerated and immunogenic in adolescents and adults.
BACKGROUND: Although decennial adult boosters of tetanus and diphtheria toxoids are recommended in Canada and the United States, a second dose of pertussis vaccine is not currently recommended for adults. METHODS: This open-label, postmarketing, multicenter study evaluated the tolerability and immunogenicity of a second dose of an adult formulation of tetanus, diphtheria, and pertussis vaccine (Tdap) in adolescents and adults 5 years after a first dose. RESULTS: A total of 545 participants from previous Tdap vaccine studies, ranging in age from 15 to 69 years, participated in this study. Of these participants, 94.2% had at least one solicited adverse event after the booster dose such as injection-site erythema (28.6%), swelling (25.6%), or pain (87.6%) or a systemic adverse event such as myalgia (61.0%), headache (53.2%), malaise (38.2%), or fever (6.5%). These adverse events were slightly more frequent than after the initial dose. Postvaccination, 100% of participants had a tetanus antibody level ≥0.10IU/mL and 95% had a diphtheria antibody level ≥0.10IU/mL. For pertussis, 82.1% (pertussis toxoid), 96.7% (filamentous hemagglutinin), 95.6% (pertactin), and 99.8% (fimbriae) had a postvaccination antibody threshold of ≥50EU/mL. CONCLUSION: A second dose of Tdap vaccine 5 years after the initial dose was well tolerated and immunogenic in adolescents and adults.
Authors: Jennifer L Liang; Tejpratap Tiwari; Pedro Moro; Nancy E Messonnier; Arthur Reingold; Mark Sawyer; Thomas A Clark Journal: MMWR Recomm Rep Date: 2018-04-27
Authors: Michael L Jackson; Onchee Yu; Jennifer C Nelson; James D Nordin; Sara Y Tartof; Nicola P Klein; James G Donahue; Stephanie A Irving; Jason M Glanz; Michael M McNeil; Lisa A Jackson Journal: Pharmacoepidemiol Drug Saf Date: 2018-06-03 Impact factor: 2.890
Authors: James C King; Yonghong Gao; Conrad P Quinn; Thomas M Dreier; Cabrini Vianney; Eric M Espeland Journal: Vaccine Date: 2015-04-05 Impact factor: 4.169
Authors: Alexis J Pillsbury; Catherine Glover; Peter Jacoby; Helen E Quinn; Parveen Fathima; Patrick Cashman; Alan Leeb; Christopher C Blyth; Michael S Gold; Thomas Snelling; Kristine K Macartney Journal: BMJ Open Date: 2018-10-18 Impact factor: 2.692